Texas Vendor Drug Program. Pharmacy Provider Procedure Manual Pricing & Reimbursement. Effective Date. March 2018

Similar documents
Covered Outpatient Drugs Federal Final Rule. Medical Assistance (MA) Program Fee-for-Service (FFS) Pharmacy Reimbursement

Texas Vendor Drug Program. Pharmacy Provider Procedure Manual Coordination of Benefits. Effective Date. February 2018

Texas Vendor Drug Program. Drug Addition Process. Effective Date. December 2017

December 15, 2017 (31 State SPAs)

NCPA Summary of CMS Medicaid Covered Outpatient Drugs AMP Final Rule Prepared January NCPA Advocacy at Work

Texas Vendor Drug Program Pharmacy Provider Procedure Manual

Archived 12.1 THE BASIS FOR ESTABLISHING A RATE OF PAYMENT DETERMINING A FEE... 2

Oklahoma Health Care Authority

Texas Vendor Drug Program. Pharmacy Provider Procedure Manual. Managed Care. Effective Date. November 2017

Texas Vendor Drug Program Pharmacy Provider Procedure Manual

M E D I C A I D P H A R M A C Y R E I M B U R S E M E N T S T A K E H O L D E R M E E T I N G

Pharmacy Stakeholder Meeting December 20, 2016

Pharmacy services: payment for prescribed drugs.

RE: Mercer Professional Dispensing Fee and Actual Acquisition Cost Analysis for Medi- Cal-Pharmacy Survey Report

APPENDIX B: VENDOR DRUG PROGRAM TEXAS MEDICAID PROVIDER PROCEDURES MANUAL: VOL. 1

SUPPLEMENTAL REBATE AGREEMENT Company Name

Texas Vendor Drug Program Pharmacy Provider Procedure Manual

Medicaid Prescription Drug Payment Reform

OREGON HEALTH AUTHORITY

340B Drug Program Compliance: Focus on Disproportionate Hospitals

National Council for Prescription Drug Programs

340B Compliance, Audits & Opportunities

Pharmacy Provider Enrollment Application

TX Health and Human Services Commission Proposed Rule: 340B Program Reimbursement

LAWS OF ALASKA AN ACT

Survey of the Average Cost of Dispensing a Medicaid Prescription in the State of Alaska

Establish fair elmbursements

Renee Gravalin, Partner

APPENDIX B: VENDOR DRUG PROGRAM TEXAS MEDICAID PROVIDER PROCEDURES MANUAL: VOL. 1

80th OREGON LEGISLATIVE ASSEMBLY Regular Session. Senate Bill 572

YOUR TRUST PLAN BENEFITS

Federal Spending on Brand Pharmaceuticals. April 2011

MICHIGAN DEPARTMENT OF HEALTH AND HUMAN SERVICES NOTICE OF PROPOSED POLICY

APPENDIX B: VENDOR DRUG PROGRAM TEXAS MEDICAID PROVIDER PROCEDURES MANUAL: VOL. 1

NATIONAL COUNCIL OF INSURANCE LEGISLATORS (NCOIL) Workers Compensation Pharmaceutical Reimbursement Rates Model Act

Medicare Part D Transition Policy CY 2018 HCSC Medicare Part D

NATIONAL COUNCILCONFERENCE OF INSURANCE LEGISLATORS (NCOIL) Model Act on Workers Compensation Repackaged Pharmaceutical Reimbursement Rates Model Act

AccessCUBICIN Enrollment Form

Glossary of Terms (Terms are listed in Alphabetical Order)

Members covered under the Extended Family Planning (EFP) plan may not be eligible for all services. EFP is not a comprehensive benefit package.

PEP-Portland Clinical Practices Policy Number: CP Policy Owner: Health Plan Operations Manager New Revised Reviewed

Assuring Medicaid Patients Access to Pharmacy Services Through Adequate Dispensing Fees

Chapter 21. Pharmacy Services

DEFICIT REDUCTION ACT OF 2005: IMPLICATIONS FOR MEDICAID PREMIUMS AND COST SHARING CHANGES

YOUR TRUST PLAN BENEFITS

BERKELEY RESEARCH GROUP. Executive Summary

Blue Essentials, Blue Advantage HMO SM and Blue Premier SM Provider Manual - Pharmacy

December 20, Howard A. Zucker, M.D., J.D. Commissioner Department of Health Corning Tower Empire State Plaza Albany, NY 12237

Committee/Subcommittee hearing bill: Health & Human Services Committee Representative Santiago offered the following:

Understanding Pharmacy Benefit Management Services

PLAN DESIGN AND BENEFITS PROVIDED BY AETNA LIFE INSURANCE COMPANY

HEATHER I. BATES Managing Director, BRG Health Analytics. BERKELEY RESEARCH GROUP, LLC 1800 M Street NW, 2 nd Floor Washington, DC 20036

Pharmacy Provider Liaison Minutes from Meeting on December 8, 2016

340B Program Contract Pharmacy Self-Audit Tool: Diversion

MEDICAID AND BUDGET RECONCILIATION: IMPLICATIONS OF THE CONFERENCE REPORT

Summary Plan Description Accenture Prescription Drug Plan

PLAN F MEDICARE (PART A) HOSPITAL SERVICES PER BENEFIT PERIOD 2019

Specialty Pharmacy Trends: Payer and Industry Considerations for Specialty Pharmacies

Prescription Drugs Spending Distribution and Cost Drivers. Steve Kappel January 25, 2007

Prescription Drug Benefits

Pharmaceutical Management Commercial Plans


340B Program Update & Recommendations for Monitoring Program Compliance October

Prescription Drug Benefits

1/16/2014. David Pointer President, SolutionsRx

PLAN F MEDICARE (PART A) HOSPITAL SERVICES PER BENEFIT PERIOD

Common Managed Care Terms & Definitions

2019 Pre-Medicare Retiree Healthcare Open Enrollment

PLAN F or HIGH DEDUCTIBLE PLAN F MEDICARE (PART A) HOSPITAL SERVICES PER BENEFIT PERIOD

August 11, Submitted electronically via Regulations.gov

Contract Summary. OptumRx Administrative Services, LLC

Changes to Small Business HMO Off Exchange plans Blue Shield of California

Health Benefits Briefing

I. PURPOSE. A. The primary objectives of Molina Healthcare s Transition Policy and Procedure are:

Florida Medicaid. Prescribed Drugs Services Coverage Policy. Agency for Health Care Administration. Draft Rule

Re: CMS-1502-P (Medicare Program; Revisions to Payment Policies Under the Physician Fee Schedule for Calendar Year 2006)

Excellus BlueCross BlueShield Participating Provider Manual. 5.0 Pharmacy Management

340B Pharmacy Program Compliance insight. ideas Kentucky Primary Care Association attention

MEDICARE PART D POLICY FORMULARY: TRANSITION PROCESS Policy Number: 6-C

PLEASE CHECK ALL BOXES THAT APPLY AND COMPLETE THE APPROPRIATE SECTION(S) OF THE FORM

Prescription Drug Pricing and Community Pharmacy NALEO Legislative Summit on Health October 21, 2017

Overview of Coverage of Drugs Under the Medicaid Medical Benefit

Understanding the Consumer Driven Health Plan. and Health Savings Account

Rate Component Overview

Steve Liles, PharmD Senior Director, Value Based Purchasing Magellan Medicaid Administration

340B Drug Pricing Program

CRS Report for Congress Received through the CRS Web


CERTIFIED RESPIRATORY CARE PRACTITIONER (CRCP) CSHCN SERVICES PROGRAM PROVIDER MANUAL

CMS Unveils 12-Step Reconciliation Process For Retiree Drug Subsidy (RDS)

Survey of the Average Cost of Dispensing a Medicaid Prescription in the State of Texas

2019 Transition Policy

Florida Agency for Health Care Administration AG Federal Awards Audit (Report# ) Six-Month Status Report as of September 30, 2014

T MaxorPlus Pharmacy Provider Manual

VERMONT SUPPLEMENTAL DRUG-REBATE AGREEMENT

Insert photo here. Common Denials. Presented by EDS Provider Field Consultants

1 SB By Senator Marsh. 4 RFD: Banking and Insurance. 5 First Read: 19-MAY-15. Page 0

Contract Summary. OptumRx Administrative Services, LLC

The Limited Income NET Program Questions and Answers for Pharmacy Providers

PLEASE CHECK ALL BOXES THAT APPLY AND COMPLETE THE APPROPRIATE SECTION(S) OF THE FORM. Patient name: Date of birth: Sex: M F

Transcription:

Texas Vendor Drug Program Pharmacy Provider Procedure Manual Pricing & Reimbursement Effective Date March 2018 The Pharmacy Provider Procedure Manual (PPPM) is available online at txvendordrug.com/about/policy/manual. i

Table of Contents Texas Vendor Drug Program... i Pharmacy Provider Procedure Manual... i Table of Contents... 1 Document History Log... 2 1 Drug Pricing... 3 2 Ingredient Cost/Reimbursement Methodologies... 4 2.1 Retail Pharmacy... 4 2.2 Long-term Care Pharmacy... 4 2.3 Specialty Pharmacy... 5 3 Professional Dispensing Fees... 5 1

Document History Log STATUS 1 REVISION 2 EFFECTIVE DESCRIPTION 3 Revision 1.4 03/01/2018 Update: 1.0 - Links Revision 1.3 11/01/2017 Update. Revision 1.2 05/01/2017 Update. Revision 1.1 01/01/2017 Update. Baseline 1.0 07/01/2016 Initial publication. 1. Status should be represented as Baseline for initial issuances, Revision for changes to the Baseline version, and Cancellation for withdrawn versions 2. Revisions should be numbered according to the version of the issuance and sequential numbering of the revision; e.g., 1.2 refers to the first version of the document and the second revision. 3. Brief description of the changes to the document made in the revision. 2

1 Drug Pricing Pursuant to the Covered Outpatient Final Rule of the Affordable Care Act of 2010, reimbursement of outpatient prescription drugs must be based on the drug's Average Acquisition Cost (AAC). Pharmacy providers must use the current Texas Drug Code Index as the reference for allowable package sizes of reimbursable legend and non-legend drugs, and will then be reimbursed at AAC plus a reasonable dispensing fee. AAC is defined as an estimate of prices generally and currently paid in the market. It may be one of the following: 1. Wholesale estimated acquisition cost (WEAC); 2. Direct acquisition cost (DEAC), according to the pharmacist's usual purchasing source and the pharmacist's usual purchasing quantity; 3. Long term care pharmacy acquisition cost (LTCPAC); or 4. Specialty pharmacy acquisition cost (SPAC) The AAC is verifiable by invoice audit conducted by Texas HHS to include necessary supporting documentation that will verify the final cost to the provider. The WEAC, LTCPAC, and SPAC prices are established using market or government sources, which include, but are not limited to: Reported manufacturer pricing First Databank Redbook Weighted Average Manufacturer Price as published by the Centers for Medicare & Medicaid Services (CMS) National Average Drug Acquisition Cost (NADAC), as published by CMS; or Gold Standard pricing service The DEAC is established by Texas HHS using direct price information supplied by a drug manufacturer. Pharmacy providers participating in the 340B Drug Pricing Program must identify all outpatient pharmacy claims filled with 340B stock for 340B-eligible people. Refer 3

to the Health Resources and Services Administration chapter of the PPPM to learn more about billing requirements for eligible pharmacies. This methodology applies to the pricing on all claims processed by Texas HHS beginning June 1, 2016. Retroactive claims will be processed with the pricing on the date of service. The change is not related to, and does not impact, reimbursement rates associated with pharmacy reimbursement through Medicaid managed care. NADAC pricing is generated by CMS and pricing disputes should be directed to CMS. Refer to the section of NADAC Pricing Questions of the Contact Information chapter of the PPPM for pricing contacts. 2 Ingredient Cost/Reimbursement Methodologies Ingredient costs may differ by the type of pharmacy and the benchmark for reimbursement is primarily the National Average Drug Acquisition Cost (NADAC), the benchmark of retail pharmacy acquisition costs developed by CMS as previously discussed. Texas HHS uses a drug s wholesale acquisition cost (WAC) price when NADAC pricing is unavailable. 2.1 Retail Pharmacy The ingredient cost is equal to the NADAC price, or (WAC minus 2 percent) if NADAC pricing is not available. 2.2 Long-term Care Pharmacy A long-term care (LTC) pharmacy is defined as one for which the total Medicaid claims for prescription drugs to residents of long term care facilities exceeds 50 percent of the pharmacy s total Medicaid claims per year. Long term care pharmacies are typically not open to the public for walk-in business. The ingredient cost is equal to (NADAC minus 2.4 percent), or (WAC minus 3.4 percent) if NADAC pricing is not available. 4

2.3 Specialty Pharmacy A specialty pharmacy is one that meets all of the following criteria: Processes more than 10% of Medicaid Specialty Claims per year compared to total claims, as described in Section 354.1853 (relating to Specialty Drugs) Obtains volume-based discounts or rebates on specialty drugs from manufacturers or wholesalers; and Dispenses at least 80 percent of filled prescriptions by shipment through the U.S. Postal Service or other common carrier to customers or healthcare professionals (including physicians and home health providers). The ingredient cost is equal to (NADAC minus 1.7 percent), or (WAC minus 8 percent) if NADAC pricing is not available. 3 Professional Dispensing Fees Payment for legend drug and non legend drug (OTC) prescriptions are reimbursed at the lesser of the following: 1. AAC plus a reasonable dispensing fee 2. The Usual and Customary (UAC) price charged the general public 3. The Gross Amount Due (GAD), if provided The reimbursement amount is determined by adding $7.93 (the fixed component) to the ingredient cost and dividing the sum by 0.9804% (the variable component). An additional $0.15 is added to that amount if the pharmacy has been certified as providing free delivery service to people enrolled in Medicaid. Another $0.50 will be added to that amount if the pharmacy dispenses a premium preferred generic. Table 1- VDP Reimbursement Calculation Value Component $7.93 Fixed component 0.9804% Variable component 5

Value Component $0.15 Delivery incentive (based on provider file) applied to all legend claims after all calculations are complete. Note: 340B pharmacies do not receive delivery incentive $0.50 Premium Preferred Generic (PPG) incentive applied to all Medicaid PPG drugs after all calculations are complete. Note: Incentive does not apply to $0.00 total payment amount claims. For example, if the ingredient cost of a drug is $10.00, the pharmacy's total reimbursement will be calculated in the following way: $10.00 plus $7.93 equals $17.93 $17.93 divided by 0.9804 equals $18.28 Pharmacies with a delivery agreement will add $0.15 equals $18.43 Pharmacies that used a premium preferred generic drug will add $0.50 equals $18.93 If the submitted UAC or GAD price for this item is less than the amount calculated above, the pharmacy will be paid the UAC or GAD price. Pharmacy staff should submit their true UAC price for all claims. The total dispensing fee shall not exceed $200 per prescription. Refer to the Enrollment chapter of the PPPM to learn more about the delivery incentive. Refer to the Drug Policy chapter of the PPPM to learn more about premium preferred generic drugs. Refer to the Health Resources and Services Administration chapter of the PPPM to learn more about requirements for 340B Drug Pricing Program eligible pharmacies. 6